Olaparib continues to show promise in very late stage prostate cancer

According to a presentation at the ongoing annual meeting of the American Association for Cancer Research (AACR) meeting here in  Philadelphia, AstraZeneca’s PARP inhibiting agent — olaparib or Lynparza — continues to show promise in very late stage metastatic, castration-resistant prostate cancer. … READ MORE …

Active surveillance today: a summary of the Sunnybrook experience and related factors

In an important new paper in Current Opinion in Urology (available free as a full-text article), Dr. Laurie Klotz has provided an excellent summary of his perspective on the current application of active surveillance in the management of low-risk prostate cancer, based on the 20-year experience of the Sunnybrook group and other data. … READ MORE …

But one OTC supplement prevents, treats prostate cancer successfully (in mice)

Having pointed out (again) that over-use of many dietary supplements can increase risk for cancer (prostate cancer included), we felt it only fair to also point out that some recent data suggest than one over-the-counter (OTC) dietary supplement seems to have the opposite effect on prostate cancer … in laboratory mice. … READ MORE …

Over-use of some supplements can increase risk for cancer

Data presented at the annual meeting of the American Association for Cancer Research here in Philadelphia have again confirmed that the use of selenium and vitamin E supplements to raise levels of these agents to higher than normal levels is not a very good idea when it comes to cancer prevention. … READ MORE …

Just how helpful is personalized genomic analysis anyway?

Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types — prostate cancer very specifically included. … READ MORE …

The monitoring of men with localized prostate cancer after first-line treatment

An article just posted in the journal Oncology offers readers a concise summary of the appropriate follow-up monitoring for men after initial, definitive treatment for localized prostate cancer who show no signs of progressive disease over time. … READ MORE …

Race, obesity, and risk for prostate cancer

By using data from the prospective SELECT trial (the Selenium and Vitamin E Cancer Prevention Trial, conducted between 2001 and 2011), researchers have been able to suggest that obesity is strongly associated with increased risk for prostate cancer diagnosis among African American males compared to non-Hispanic whites. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,260 other followers